Evidence map›Paper›PMID 42141154›Full record

ArticleBritish journal of cancer2026

Lethal clinical outcome and immuno-fibrotic contexture in refractory urothelial carcinoma harboring MYC amplification and overexpression.

Lingkai Zhang, Zhaopei Liu, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Jinming Shi, Xiaohe Su, Kaifeng Jin, Han Zeng, Yuan Chang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lingkai Zhang *National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Zhaopei Liu *Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-5288-5037
Yawei DingDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Jiaxing SunDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Yuzhen WuDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Jinming ShiDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Xiaohe SuNational Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Kaifeng JinNational Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-9867-6516
Han ZengDepartment of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China.ORCID http://orcid.org/0000-0001-6486-2038
Yuan ChangDepartment of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Le XuDepartment of Urology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Weijuan ZhangDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0003-3494-3114
Zewei WangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-8833-3541
Hailong LiuDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yu ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Jiejie XuNational Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China. jjxufdu@fudan.edu.cn.ORCID http://orcid.org/0000-0001-7431-9063

Funding

China Postdoctoral Science Foundation BX20230091, 2024M760547Chinese Society of Clinical Oncology (Chinese Society of Clinical Oncology, Beijing Xisike Clinical Oncology Research Foundation) Y-Gilead2024-PT-0098National Natural Science Foundation of China (National Science Foundation of China) 82272786, 82272930, 82372793, 82373276, 8250373, 82573675Natural Science Foundation of Shanghai (Natural Science Foundation of Shanghai Municipality) 22ZR1413400, 23ZR1440300, 23ZR1411700, 24SF1901304Shanghai Municipal Health Bureau (Shanghai Municipal Public Health Bureau) 202340127, 202340195，20224Y0232
6 · The paper itself

Abstract

backgroundThe MYC proto-oncogene is frequently overexpressed (OE) and orchestrates key programs in urothelial carcinoma (UC). However, its impact on clinical outcomes, biological behaviors, and tumor microenvironment (TME) in UC patients remains unclear.

methodsThis study included 250 UC patients with matched clinical annotations from two in-house cohorts (ZSHS and FUSCC cohorts). The MYC status was determined by immunohistochemical analysis and targeted sequencing. We investigated the associations between MYC status and clinical outcomes, tumor biological behaviors, and TME features. Additionally, 1603 UC patients from three external datasets were used for validations.

resultsMYC OE was detected in 25.2% of UC patients, and was associated with advanced tumor stage, higher histological grade, and the presence of lymphovascular invasion in the ZSHS cohort. Patients with MYC OE or MYC amplification delineated the worst prognosis and exhibited resistance to platinum-based chemotherapy and PD-(L)1 blockade, independent of classical basal/luminal status. Mechanistically, MYC-OE UC displayed a hybrid/partial EMT phenotype characterized by high-grade tumor budding. This unique cellular state co-occurs with TGFB1-related fibrogenesis and immunosuppression.

conclusionsMYC OE defines a lethal subtype with aggressive behaviors and therapeutic resistance in UC patients. Our findings highlight the need for tailored therapeutic strategies for this refractory subtype of UC.

Indexed as

Carcinoma, Transitional CellProto-Oncogene Proteins c-mycUrinary Bladder NeoplasmsAgedDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionFemaleFibrosisGene AmplificationHumansMaleMiddle AgedPrognosisProto-Oncogene MasTransforming Growth Factor beta1Tumor MicroenvironmentMAS1 protein, humanMYC protein, humanProto-Oncogene MasProto-Oncogene Proteins c-mycTransforming Growth Factor beta1

Identifiers

PMID42141154
PMCPMC13427758

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.